- Administered via intravenous infusion and will also be studied via subcutaneous injection
- Ofatumumab is being studied in RRMSLike Rituxan and ocrelizumab, this drug is an anti-CD20 monoclonal antibody. It has the potential advantage of being a human monoclonal antibody (versus antibodies from non-human species that have been modified),Ofatumumab has a unique target on the CD20 molecule and is approved for certain forms of leukemia. Genmab announced positive interim results for a Phase II safety and pharmacokinetics (how the body processes the drug) study of ofatumumab in 2010. This study had 38 patients who were randomized to ofatumumab or placebo in a cross-over design. The number of gadolinium-enhancing lesions and new or enlarging T2 lesions was statistically significantly less in patients treated with ofatumumab compared to placebo.
Another Phase II study, MIRROR29, will compare several doses of ofatumumab administered subcutaneously to placebo in RRMS and plans to enroll approximately 200 patients. This study is expected to run through 2015.